ADYNOVI
2000IU INJ PSO LQF 1+1X5ML II
| Maximum ex-factory price/Ex-factory price ? | 41419,29 CZK |
|---|---|
| Legal basis of maximum ex-factory price/ex-factory price ? | Maximum ex-factory price announced under the law. |
Informace o základní úhradě
| Core reimbursement from health insurance ? | 20854,05 CZK |
|---|---|
| Maximum reimbursement from health insurance ? | 24656,64 CZK |
| Legal basis of reimbursement from health insurance ? | Reimbursement set by the law. |
| Indication restriction of reimbursement ? | Přípravek je hrazen u pacientů ve věku 12 let a více, kteří jsou zároveň předléčeni léčivým přípravkem s obsahem plazmatického nebo rekombinantního koagulačního faktoru VIII, minimálně 150 expozičními dny, a to: 1) v prevenci a léčbě krvácivých stavů u nemocných s vrozeným či získaným nedostatkem faktoru VIII 2) u nemocných s výskytem inhibitoru proti faktoru VIII v nízkém titru (do 5 Bethesda jednotek). |
| Prescribing doctor's specialisation ? | Hematology and transfusion medicine, pediatric oncology a hematology |
| Reporting limit ? |
AE:
Unless it is advisable to transfer the prescription of the product to another doctor under paragraph 2 in light of the effect and safety of the product, the "E" symbol will mark the product in the decision. The decision shall allocate the "A" symbol to products administered, in light of its nature, by a doctor in outpatient care. This product shall be charged to the health insurer along with the relevant intervention as a separately charged product. If advisable given the effect and safety of the product or if in the public interest, reporting of "A" products shall be restricted to doctors with specialist capacity, with the specialist field stated in the decision. |
| Rough price for the final consumer ? | 47416,24 CZK |
| Rough payment for the final consumer (for 1 prescribed package dispensed) ? | 22759.6 CZK |
| Eligible extra payment ? | – |
| Eligible extra payment for individuals aged 65 and older ? | – |
cz